↓ Skip to main content

The Niacin/Butyrate Receptor GPR109A Suppresses Mammary Tumorigenesis by Inhibiting Cell Survival

Overview of attention for article published in Cancer Research, February 2014
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (95th percentile)
  • High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

twitter
55 tweeters

Citations

dimensions_citation
87 Dimensions

Readers on

mendeley
87 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
The Niacin/Butyrate Receptor GPR109A Suppresses Mammary Tumorigenesis by Inhibiting Cell Survival
Published in
Cancer Research, February 2014
DOI 10.1158/0008-5472.can-13-1451
Pubmed ID
Authors

Selvakumar Elangovan, Rajneesh Pathania, Sabarish Ramachandran, Sudha Ananth, Ravi N. Padia, Ling Lan, Nagendra Singh, Pamela M. Martin, Lesleyann Hawthorn, Puttur D. Prasad, Vadivel Ganapathy, Muthusamy Thangaraju

Abstract

GPR109A, a G-protein-coupled receptor, is activated by niacin and butyrate. Upon activation in colonocytes, GPR109A potentiates anti-inflammatory pathways, induces apoptosis, and protects against inflammation-induced colon cancer. In contrast, GPR109A activation in keratinocytes induces flushing by activation of Cox-2-dependent inflammatory signaling, and the receptor expression is upregulated in human epidermoid carcinoma. Thus, depending on the cellular context and tissue, GPR109A functions either as a tumor suppressor or a tumor promoter. However, the expression status and the functional implications of this receptor in the mammary epithelium are not known. Here, we show that GPR109A is expressed in normal mammary tissue and, irrespective of the hormone receptor status, its expression is silenced in human primary breast tumor tissues, breast cancer cell lines, and in tumor tissues of three different murine mammary tumor models. Functional expression of this receptor in human breast cancer cell lines decreases cyclic AMP production, induces apoptosis, and blocks colony formation and mammary tumor growth. Transcriptome analysis revealed that GPR109A activation inhibits genes, which are involved in cell survival and antiapoptotic signaling, in human breast cancer cells. In addition, deletion of Gpr109a in mice increased tumor incidence and triggered early onset of mammary tumorigenesis with increased lung metastasis in MMTV-Neu mouse model of spontaneous breast cancer. These findings suggest that GPR109A is a tumor suppressor in mammary gland and that pharmacologic induction of this gene in tumor tissues followed by its activation with agonists could be an effective therapeutic strategy to treat breast cancer.

Twitter Demographics

The data shown below were collected from the profiles of 55 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 87 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Netherlands 1 1%
Italy 1 1%
Unknown 85 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 19 22%
Student > Master 16 18%
Student > Ph. D. Student 15 17%
Student > Bachelor 12 14%
Student > Doctoral Student 4 5%
Other 8 9%
Unknown 13 15%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 20 23%
Agricultural and Biological Sciences 14 16%
Medicine and Dentistry 13 15%
Immunology and Microbiology 8 9%
Pharmacology, Toxicology and Pharmaceutical Science 4 5%
Other 9 10%
Unknown 19 22%

Attention Score in Context

This research output has an Altmetric Attention Score of 36. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 June 2022.
All research outputs
#876,905
of 21,513,077 outputs
Outputs from Cancer Research
#604
of 17,428 outputs
Outputs of similar age
#9,219
of 199,668 outputs
Outputs of similar age from Cancer Research
#8
of 148 outputs
Altmetric has tracked 21,513,077 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 17,428 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.4. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 199,668 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 148 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.